March 2, 2021 – 3D Medicines Inc. announced the appointment of Shen Xiao, M.D., Ph.D., as Chief Strategy Officer. He would be responsible for tasks including strategic innovation, competitive positioning and business model establishment for the company, he would provide support for the Chief Executive Officer on strategy planning and execution, and be in charge of the Regulatory Affairs Department. Shen Xiao, M.D., Ph.D., would report to John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines.

February 26, 2021 – the construction of 3D Medicines’ R&D and Manufacturing Center was officially started, which was announced at the Xuzhou venue of the Joint Groundbreaking Ceremony of Jiangsu Province, as one of the 2021 Key Projects in Jiangsu.

January 29, 2021 – 3D Medicines Inc. announced that the National Medical Products Administration (NMPA) has granted the IND approval for 3D011, a Class 1 innovative drug self-developed by 3D Medicines for the treatment of advanced solid tumors.

January 19, 2021 – 3D Medicines Inc. announced that the NDA of Envafolimab (KN035), the recombinant humanized PD-L1 single-domain antibody on which 3D Medicines has established a strategic collaboration with Alphamab Oncology (9966.HK) and Simcere Pharmaceutical Group Limited (2096.HK), was granted Priority Review by the Center for Drug Evaluation (CDE) under National Medical Products Administration (NMPA).

Shanghai (China), Daejeon (South Korea)，January 5th 2021 - 3D Medicines Inc., a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated immuno-oncology drugs, and Y-Biologics, the South Korean biotech company, have entered into a license agreement, and 3D Medicines will obtain exclusive rights to develop, manufacture, and commercialize YBL-013, a T cell bi-specific engager based on ALiCE platform technology, in the Territory of Greater China (mainland China, Hong Kong, Macau and Taiwan) and will co-developed it across the globe. For 3D Medicines, acquiring this candidate drug will further improve its product layout in the field of immune-oncology, and build a highly competitive and complementary pipeline.